CClinicalTrials.gg
Active, not recruitingNCT05868044RESPONSEUpdated Apr 23, 2026

REsponse to Combined SONS and ONS in Chronic Cluster headachE

An interventional study of PRIMUS in Chronic Cluster Headache, sponsored by Salvia BioElectronics. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Salvia BioElectronics · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.

02

Conditions studied

  • Chronic Cluster Headache

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Able and willing to provide informed consent
  • Documented chronic cluster headache for at least 1 year as per ICHD-3 criteria
  • Attack frequency of ≥ 4 attacks per week for ≥ 4 weeks before enrolment
  • Documented failure of verapamil (failure meaning ineffective, provoked unacceptable side-effects or contra-indicated)
  • Stable on preventive treatment for at least two weeks prior to enrolment.
  • Agree to refrain from starting new prophylactic cluster headache medication or other preventive treatments, from 4 weeks before entering the baseline period throughout the duration of the study
  • MRI available (not older than 4 years prior to study enrolment) or willing to undergo an MRI to exclude structural lesions potentially causing headache
  • Able and willing to complete a headache Diary

Main Exclusion Criteria:

  • Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from cluster headache attacks based on the quality and associated symptoms
  • Concomitant neuromodulation, except tVNS
  • Previous failure to any implantable neuromodulation device for neurovascular headache
  • Have an existing Active Implantable Medical Device nearby the implant location (e.g. DBS, cochlear implant, …)
  • Metal implants in the skull (e.g. skull plates, seeds) nearby the implant
  • Have a pacemaker or implantable cardioverter defibrillator (ICD)
  • Suboccipital infiltrations with steroids and/or local anaesthetics or use of oral steroids in the past 3 months
  • Use of botulinum toxin injections in the past 12 weeks
  • Calcitonin gene-related peptide inhibitors started less than 12 weeks prior to enrolment
  • Women of childbearing age who are pregnant, nursing or not using contraception
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    PRIMUS

    PRIMUS system

    Device: PRIMUS

Interventions

  • DevicePRIMUS

    PRIMUS system

05

What researchers measure

Primary outcomes

  1. Safety Evaluation

    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at 30 days.

    Time frame: 4 weeks

  2. Safety Evaluation

    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at the end of the study.

    Time frame: 12 months

06

Study locations

1 site
  • Resolve Pain
    Buderim, Queensland 4556, Australia
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05868044
Lead sponsor
Salvia BioElectronics
Responsible party
Sponsor
First posted
May 22, 2023
Start date
May 2, 2023
Primary completion
Apr 23, 2024
Completion
Dec 30, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

Paul Frank, MD
principal investigator · Resolve Pain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion